HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

(17(20)E)-21-norpregnene

azole derivatives supress growth of prostate carcinoma

Also Known As:

alsevirone

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Fused-Ring Compounds
  - Steroids: 70059
    - Norsteroids: 16
      - Norpregnanes: 2
        Norpregnadienes
        (17(20)E)-21-norpregnene: 1

Experts

1.	Anisimova, Natalia Y: 1 article (01/2022)
2.	Karshieva, Saida S: 1 article (01/2022)
3.	Khan, Irina I: 1 article (01/2022)
4.	Komarova, Marina V: 1 article (01/2022)
5.	Latysheva, Alexandra S: 1 article (01/2022)
6.	Misharin, Alexander Y: 1 article (01/2022)
7.	Nitetskaya, Tatiana A: 1 article (01/2022)
8.	Pokrovsky, Vadim S: 1 article (01/2022)
9.	Sokolova, Darina V: 1 article (01/2022)
10.	Spirina, Tatiana S: 1 article (01/2022)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 01/01/2022 - "The aim of this study was to explore the mechanisms of action of alsevirone in prostate cancer (PC) in vitro and in vivo: CYP17A1 inhibition, cytotoxic, apoptotic, and antitumor effects in comparison with abiraterone. " 01/01/2022 - "Antiproliferative, proapoptotic, and tumor-suppressing effects of the novel anticancer agent alsevirone in prostate cancer cells and xenografts."
2.	Neoplasms (Cancer) 01/01/2022 - "In 22Rv1 xenografts, alsevirone 300 mg/kg × 10/24 h per os inhibited tumor growth: on Day 9 of treatment, tumor growth inhibition = 59% (p = .022). " 01/01/2022 - "Antiproliferative, proapoptotic, and tumor-suppressing effects of the novel anticancer agent alsevirone in prostate cancer cells and xenografts."

Related Drugs and Biologics

1.	abiraterone
2.	Antineoplastic Agents (Antineoplastics)